MedTrace Logo

Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies

NCT06028074 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 111

Last updated 2025-07-11

No results posted yet for this study

Summary

GIM-122 is a first-in-class, humanized immunoglobulin G1 kappa dual functioning monoclonal antibody (DFA). This phase 1 / 2 study plans to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of intravenous (IV) administration of GIM-122 in adults with advanced malignancies.

Conditions

  • Advanced Solid Malignancies

Interventions

DRUG

GIM122

GIM-122 administered IV once every 3 weeks or every 2 weeks

Sponsors & Collaborators

  • Georgiamune Inc

    lead INDUSTRY

Principal Investigators

  • Omid Hamid, MD · The Angeles Clinic and Research Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-12
Primary Completion
2026-09-30
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06028074 on ClinicalTrials.gov